16 Dec 2019 16:05
Â
Â
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Â
Director / PDMR Shareholding
Â
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that Kieron Harbinson, Group Finance Director, has sold and bought back 4,554 Ordinary Shares in the Company. Mr Harbinson's ownership of shares in the Company therefore remains unchanged.
Â
The sale of 4,554 Ordinary Shares was conducted at 11.2 pence per share on 11 December 2019 by Mr Harbinson's pension administrator, without his knowledge or consent. Mr Harbinson was notified of the sale on 13 December 2019 and immediately re-purchased the Ordinary Shares into his ISA, at a price of 13.49 pence per Ordinary Share.
Â
Mr Harbinson's ownership of Ordinary Shares in the Company remains unchanged at 681,617 Ordinary Shares, representing 0.45 per cent. of the issued share capital of the Company.
Â
The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below.
Â
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Â
Â
Contacts:Â
Â
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
David Evans, Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | Mob: 07740 084452 |
 |  |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Hannah Boros (Corporate Finance) | Â |
Camille Gochez (Corporate Broking) | Â |
 |  |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Â
Â
Â
 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Keiron Harbinson | ||||
 | Reason for the notification | |||||
a) | Position/status: | Group Finance Director | ||||
b) | Initial notification/Amendment: | Initial Notification | ||||
 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Omega Diagnostics Group Plc | ||||
b) | LEI: | 2138007U9P4BTZTYIR92 | ||||
 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 0.5 pence each GB00B1VCP282 Â | ||||
b) | Nature of the transaction: | Sale of Ordinary Shares | ||||
c) | Price(s) and volume(s): |
 | ||||
d) | Aggregated information: ·; Aggregated volume: ·; Price: | Single transaction as in 4 c) above
 | ||||
e) | Date of the transaction: | 11 December 2019 | ||||
f) | Place of the transaction: | LSE | ||||
Â
 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Keiron Harbinson | ||||
 | Reason for the notification | |||||
a) | Position/status: | Group Finance Director | ||||
b) | Initial notification/Amendment: | Initial Notification | ||||
 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Omega Diagnostics Group Plc | ||||
b) | LEI: | 2138007U9P4BTZTYIR92 | ||||
 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 0.5 pence each GB00B1VCP282 Â | ||||
b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s): |
 | ||||
d) | Aggregated information: ·; Aggregated volume: ·; Price: | Single transaction as in 4 c) above
 | ||||
e) | Date of the transaction: | 16 December 2019 | ||||
f) | Place of the transaction: | LSE | ||||
Â